Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma
NCT06171321Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Dec 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tegafur in biliary tract cancer (BTC) (2 arms), sponsored by Shanghai East Hospital. Primary endpoints: Disease Free Survival at 2 years, Sensitivity of postoperative ctDNA at 60 months and 2 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
tegafur
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06171321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171321.